ebselen has been researched along with masitinib in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dou, X; Guo, Z; Huo, T; Jiao, N; Lai, L; Liu, Y; Liu, Z; Lu, Y; Song, S; Su, L; Sun, Q; Wang, B; Wang, C; Xu, G; Yu, Z; Zhang, C; Zhang, L; Zhao, X | 1 |
1 other study(ies) available for ebselen and masitinib
| Article | Year |
|---|---|
Discovery of 2-(furan-2-ylmethylene)hydrazine-1-carbothioamide derivatives as novel inhibitors of SARS-CoV-2 main protease.
Topics: Antiviral Agents; Coronavirus 3C Proteases; COVID-19 Drug Treatment; Drug Discovery; Furans; Humans; Hydrazines; Molecular Docking Simulation; Protease Inhibitors; SARS-CoV-2 | 2022 |